Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 9/2018

01-09-2018 | Benign Prostatic Hyperplasia (K McVary, Section Editor)

Is Tamsulosin Linked to Dementia in the Elderly?

Authors: Jason K. Frankel, Yinghui Duan, Peter C. Albertsen

Published in: Current Urology Reports | Issue 9/2018

Login to get access

Abstract

Purpose of Review

Lower urinary tract symptoms (LUTS) result from age-related changes in detrusor function and prostatic growth that are driven by alterations in the ratio of circulating androgens and estrogens. Alpha-adrenergic receptor blockers are commonly used to treat LUTS because they influence urethral tone and intra-urethral pressure. Molecular cloning studies have identified three α1-adrenergic receptor subtypes (α1A, α1B, and α1D). The α1A subtype is predominant in the human prostate but is also present in many parts of the brain that direct cognitive function. Tamsulosin is the most widely used α1-adrenergic receptor antagonist with 12.6 million prescriptions filled in 2010 alone. When compared to the other common types of α1-adrenergic receptor antagonists (i.e., terazosin, doxazosin, and alfuzosin), tamsulosin is 10- to 38-fold more selective for the α1A versus the α1B subtype.

Recent Findings

Duan et al. have recently shown that men taking tamsulosin have a higher risk of developing dementia when compared to men taking other α-adrenergic antagonists or no α-adrenergic antagonists at all (HR 1.17; 95% CI 1.14–1.21).

Summary

Based upon this retrospective analysis, we believe that tamsulosin, because of its unique affinity for α1A-adrenergic receptors, may increase the risk of developing dementia when used for an extended period of time. If these findings are confirmed, they carry significant public health implications for an aging society.
Literature
1.
McConnell JD. Prostatic growth: new insights into hormonal regulation. Br J Urol. 1995;76(Suppl 1):5–10.PubMed
2.
Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 1987;317(10):599–604.CrossRefPubMed
3.
4.
Kyprianou N, Isaacs JT. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol. 1989;3(10):1515–22.CrossRefPubMed
5.
Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol. 1992;147(5):1293–7.CrossRefPubMed
6.
Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004;171(3):1029–35.CrossRefPubMed
7.
Lepor H, Tang R, Meretyk S, Shapiro E. Alpha 1 adrenoceptor subtypes in the human prostate. J Urol. 1993;149(3):640–2.CrossRefPubMed
8.
Lepor H, Tang R, Shapiro E. The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate. 1993;22(4):301–7.CrossRefPubMed
9.
Honda K, Miyata-Osawa A, Takenaka T. Alpha 1-adrenoceptor subtype mediating contraction of the smooth muscle in the lower urinary tract and prostate of rabbits. Naunyn Schmiedeberg's Arch Pharmacol. 1985;330(1):16–21.CrossRef
10.
Lepor H, Gup DI, Baumann M, Shapiro E. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology. 1988;32(6 Suppl):21–6.PubMed
11.
Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147(Suppl 2):S88–119.CrossRefPubMedPubMedCentral
12.
Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978;50(7):551–4.CrossRefPubMed
13.
Berthelsen S, Pettinger WA. A functional basis for classification of alpha-adrenergic receptors. Life Sci. 1977;21(5):595–606.CrossRefPubMed
14.
Hedlund H, Andersson KE, Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol. 1983;130(2):275–8.CrossRefPubMed
15.
Andersson KE, Lepor H, Wyllie MG. Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997;30(3):202–15.CrossRefPubMed
16.
Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol. 1993;150(2 Pt 1):546–51.CrossRefPubMed
17.
Kobayashi S, Tang R, Wang B, Opgenorth T, Stein E, Shapiro E, et al. Localization of endothelin receptors in the human prostate. J Urol. 1994;151(3):763–6.CrossRefPubMed
18.
Walden PD, Durkin MM, Lepor H, Wetzel JM, Gluchowski C, Gustafson EL. Localization of mRNA and receptor binding sites for the alpha 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J Urol. 1997;157(3):1032–8.CrossRefPubMed
19.
20.
Rokosh DG, Simpson PC. Knockout of the alpha 1A/C-adrenergic receptor subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci U S A. 2002;99(14):9474–9.CrossRefPubMedPubMedCentral
21.
Cavalli A, Lattion AL, Hummler E, Nenniger M, Pedrazzini T, Aubert JF, et al. Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor. Proc Natl Acad Sci U S A. 1997;94(21):11589–94.CrossRefPubMedPubMedCentral
22.
Tanoue A, Nasa Y, Koshimizu T, Shinoura H, Oshikawa S, Kawai T, et al. The alpha(1D)-adrenergic receptor directly regulates arterial blood pressure via vasoconstriction. J Clin Invest. 2002;109(6):765–75.CrossRefPubMedPubMedCentral
23.
Lapiz MD, Morilak DA. Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience. 2006;137(3):1039–49.CrossRefPubMed
24.
Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, Weinshenker D. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci U S A. 2007;104(34):13804–9.CrossRefPubMedPubMedCentral
25.
Stone EA, Quartermain D. Alpha-1-noradrenergic neurotransmission, corticosterone, and behavioral depression. Biol Psychiatry. 1999;46(9):1287–300.CrossRefPubMed
26.
Sirvio J, MacDonald E. Central alpha1-adrenoceptors: their role in the modulation of attention and memory formation. Pharmacol Ther. 1999;83(1):49–65.CrossRefPubMed
27.
Doze VA, Papay RS, Goldenstein BL, Gupta MK, Collette KM, Nelson BW, et al. Long-term alpha1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity. Mol Pharmacol. 2011;80(4):747–58.CrossRefPubMedPubMedCentral
28.
Knauber J, Muller WE. Decreased exploratory activity and impaired passive avoidance behaviour in mice deficient for the alpha(1b)-adrenoceptor. Eur Neuropsychopharmacol. 2000;10(6):423–7.CrossRefPubMed
29.
Spreng M, Cotecchia S, Schenk F. A behavioral study of alpha-1b adrenergic receptor knockout mice: increased reaction to novelty and selectively reduced learning capacities. Neurobiol Learn Mem. 2001;75(2):214–29.CrossRefPubMed
30.
Sadalge A, Coughlin L, Fu H, Wang B, Valladares O, Valentino R, et al. Alpha 1d adrenoceptor signaling is required for stimulus induced locomotor activity. Mol Psychiatry. 2003;8(7):664–72.CrossRefPubMed
31.
Nalepa I, Kreiner G, Bielawski A, Rafa-Zablocka K, Roman A. Alpha1-adrenergic receptor subtypes in the central nervous system: insights from genetically engineered mouse models. Pharmacol Rep. 2013;65(6):1489–97.CrossRefPubMed
32.
McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803.CrossRefPubMed
33.
Lepor H. Alpha-blockers for the treatment of benign prostatic hyperplasia. Urol Clin North Am. 2016;43(3):311–23.CrossRefPubMed
34.
35.
Martin DJ, Lluel P, Guillot E, Coste A, Jammes D, Angel I. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther. 1997;282(1):228–35.PubMed
36.
Andersson KE, Wyllie MG. Ejaculatory dysfunction: why all alpha-blockers are not equal. BJU Int. 2003;92(9):876–7.CrossRefPubMed
37.
Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006;97(Suppl 2):34–8. discussion 44-5CrossRefPubMed
38.
Nikolic K, Filipic S, Smolinski A, Kaliszan R, Agbaba D. Partial least square and hierarchical clustering in ADMET modeling: prediction of blood-brain barrier permeation of alpha-adrenergic and imidazoline receptor ligands. J Pharm Pharm Sci. 2013;16(4):622–47.CrossRefPubMed
39.
Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience. 2007;146(1):471–80.CrossRefPubMedPubMedCentral
40••.
Duan Y, Grady JJ, Albertsen PC, Helen Wu Z. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol Drug Saf. 2018;27(3):340–8. This is the first report linking tamsulosin to the risk of developing dementia. The authors outline a plausible mechanism of action and provide support from Medicare claims data
41.
Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement. 2016;12(3):216–24.CrossRefPubMedPubMedCentral
42.
43•.
Gill SS, Bai AD. Beta testing the potential link between the alpha antagonist tamsulosin and dementia. Pharmacoepidemiol Drug Saf. 2018;27(3):349–50. This editorial comment accompanied reference #40. The authors support the idea of a causal link between tamsulosin and dementia and encourage future trials to prove this relationship CrossRefPubMed
Metadata
Title
Is Tamsulosin Linked to Dementia in the Elderly?
Authors
Jason K. Frankel
Yinghui Duan
Peter C. Albertsen
Publication date
01-09-2018
Publisher
Springer US
Published in
Current Urology Reports / Issue 9/2018
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-018-0821-0

Other articles of this Issue 9/2018

Current Urology Reports 9/2018 Go to the issue

Benign Prostatic Hyperplasia (K McVary, Section Editor)

Costs of Managing Benign Prostatic Hyperplasia in the Office and Operating Room

Benign Prostatic Hyperplasia (K McVary, Section Editor)

Comparison of Robot-Assisted Versus Open Simple Prostatectomy for Benign Prostatic Hyperplasia

Prostate Cancer (S Prasad, Section Editor)

Castration-Resistant Prostate Cancer: Sequencing Oral and Infusion Agents

Men's Health (A Dabaja, Section Editor)

Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Voiding Dysfunction After Non-urologic Pelvic Surgery

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Management of Postoperative Lower Urinary Tract Symptoms (LUTS) After Pelvic Organ Prolapse (POP) Repair